EVENTS | VIEW CALENDAR
Off to see the wizard
HACKENSACK, N.J.—Since the "war on cancer" was declared in the United States some 40 years ago, early detection tests, improved treatments, anti-cigarette campaigns and smoke-free environments have proven effective in reducing the number of many cancers. But statistics, according to the American Cancer Society, show the number of new cases and death rates have not decreased for ovarian cancer—the deadliest of all gynecologic cancers.
However, the fight against ovarian cancer has begun with the joint collaboration of the John Theurer Cancer Center of Hackensack, N.J., and leading global genomics service provider Genewiz. The cancer center and genomics firm on June 26 announced a new partnership aimed at combining efforts toward the advancement of ovarian cancer biomarker discovery research.
The research collaboration will enable analysis of ovarian cancer samples for the identification of biomarkers predicting prognosis and chemotherapy outcomes for ovarian cancer. The joint agreement calls for Genewiz to process and analyze clinical samples supplied by the Theurer Cancer Center in CLIA-certified, CAP-accredited laboratories located at Genewiz's global headquarters in South Plainfield, N.J.
"Genewiz's cutting-edge genomic analysis technologies and informatics capabilities, including our recently launched OncoGxOne Discovery ovarian cancer panel, enable us to comprehensively assay ovarian cancer-related genes for the detection of all types of genomic aberrations, including gene fusions and copy number variance, in addition to point mutations," stated Dr. Shihong Li, a Genewiz principal investigator.
"Working with Genewiz offers the confidence of proven competencies in comprehensive genomic analysis for cancer research, as well as the benefit of having a CLIA-certified, CAP-accredited laboratory for working with our clinical samples," added Dr. K. Stephen Suh, principal investigator at the Theurer Cancer Center. "We are excited to work together for the improvement of cancer care and women's health overall."
According to the American Cancer Society, in 2013, an estimated 22,240 new cases of ovarian cancer will be diagnosed, and 14,030 women will die of the disease in the United States.
Genewiz is a global contract research organization specializing in genomic services, including DNA sequencing, gene synthesis, molecular biology, genomic, bioinformatics and GxP/CLIA regulatory-compliant services. Genewiz is a privately held global enterprise with locations in Boston; Washington, D.C.; Research Triangle Park, N.C.; San Diego; San Francisco; and Seattle. International locations include Beijing; Suzhou, China; London and Osaka, Japan. Genewiz claims it leads the industry in outsourcing partnerships with pharmaceutical, biotechnology, clinical, academic and government institutions.
The Theurer Cancer Center at Hackensack University Medical Center is among the nation's top 50 U.S. News and World Report's Best Hospitals for cancer—the highest-ranked facility in New Jersey with this designation. It is New Jersey's largest and most comprehensive cancer center dedicated to the diagnosis, treatment, management, research, screenings and preventive care, as well as survivorship of patients with all types of cancer.